The Rise Of Personalized Medicine Is Fueling The Growth Of The Market Due To Its Role In Enhancing Treatment Precision And Targeted Therapy Effectiveness Is Supporting Development Across The Molecular Targeted Therapy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Molecular Targeted Therapy Market Projected To Expand During 2026–2030?

The molecular targeted therapy market size has seen robust growth in recent years. This market is expected to increase from $71.64 billion in 2025 to $77.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. The expansion observed in the past can be linked to factors like cancer genomics research, monoclonal antibody development, numerous oncology drug approvals, the emergence of hospital oncology centers, and the widespread expansion of clinical trials.

The molecular targeted therapy market is projected to expand significantly in the coming years. Its size is expected to reach $107.64 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.4%. This anticipated growth throughout the forecast period stems from factors such as the expansion of personalized cancer treatment, wider adoption of next-generation sequencing, AI-driven advancements in drug discovery, the escalating global oncology burden, and supportive targeted therapy reimbursement policies. Prominent trends for the same period include the broadening of precision oncology, a greater embrace of biomarker-based therapies, the development of targeted cancer drug pipelines, the incorporation of companion diagnostics, and an increasing reliance on combination targeted therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

Which Growth Factors Are Strengthening The Molecular Targeted Therapy Market Landscape?

The expanding influence of personalized medicine is projected to stimulate the growth of the molecular targeted therapy market moving forward. Personalized medicine constitutes a healthcare methodology that customizes medical interventions and preventative measures based on an individual’s genetic makeup, lifestyle, and environmental factors. Its increasing prevalence is attributed to the growing availability of genetic data, which facilitates treatments precisely adapted to individual genomes for improved efficacy and fewer side effects. Personalized medicine supports molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, thereby enabling the selection of therapies that directly address these abnormalities. This approach enhances treatment precision and minimizes harm to healthy tissues. For illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA sanctioned 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the advancement of personalized medicine is a primary force driving the expansion of the molecular targeted therapy market.

How Does Segment Analysis Break Down The Molecular Targeted Therapy Market Structure?

The molecular targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy

2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous

3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications

4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors

3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing

4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

What Trends Are Driving Changes In The Molecular Targeted Therapy Market?

Major companies in the molecular targeted therapy market are concentrating on creating advanced products, such as small molecule inhibitors, to enhance patient results across various cancers and chronic diseases. Small molecule inhibitors are tiny compounds designed to easily enter cells and suppress specific proteins that contribute to disease progression. For instance, in January 2025, Amgen Inc., a US-based pharmaceutical company, launched Lumakras (sotorasib) in conjunction with Vectibix (panitumumab), which secured approval from the US Food and Drug Administration (FDA), a US-based government organization. This therapy is indicated for adult patients suffering from KRAS G12C-mutated metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved test. The basis for this approval was the Phase 3 CodeBreaK 300 trial, where the combination therapy significantly more than doubled progression-free survival compared to the standard of care investigated, marking it as the first targeted therapy to demonstrate such a benefit in this patient population resistant to chemotherapy.

Who Are The Businesses Driving Activity In The Molecular Targeted Therapy Market?

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Access The Complete Molecular Targeted Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

Which Geographic Region Represents The Largest Molecular Targeted Therapy Market Share?

North America was the largest region in the molecular targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Molecular Targeted Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

Browse Through More Reports Similar to the Global Molecular Targeted Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795